Despite long-term antiretroviral therapy, cerebrospinal HIV reservoirs have been identified in individuals living with the virus and linked with a higher rate of cognitive defects.
Browsing: Neurological Complications
A new computational model has revealed the mechanism of replication in prions, potentially opening new avenues for drug development against prion diseases.
New research investigating possible interactions between Epstein–Barr virus and neurological diseases has successfully infected neuronal-like cells in vitro, with the hope to use these as a model for studying this virus in the future.
Maternal infections, including influenza, can lead to higher rates of adverse fetal outcomes. New research suggests high levels of choline during gestation could mitigate this impact.
Individuals with schizophrenia also have higher level of antibodies against the Epstein-Barr virus, according to new research.
Researchers have discovered Candida albicans can cross the blood–brain barrier, triggering an immune response that results in the formation of granuloma-type structures and memory impairments.
New research has suggested that the spread of prions to the brain does not occur via the blood–brain barrier, implicating other mechanisms.
IDWeek: Could antiretroviral therapy efavirenz increase the risk of neurological conditions in offspring?
Antiretroviral therapy with efavirenz in HIV-positive pregnant women has been reported to increase the risk of neurological conditions in offspring.
A recent study, utilizing new research methods, has demonstrated how Zika virus may suppress gene transcription reducing immune response in human macrophage cells.
We take a look at the drugs that have been studied as treatments for confirmed prion diseases in humans – either in clinical trials, or on a compassionate, case-by-case basis – and look at what the future might hold for the treatment of prion diseases.